Having previously set out to be at the forefront of the biosimilars space, Boehringer Ingelheim GmbH is now only pursuing one – a version of Humira and then only in the US - deciding instead to stick to the innovative route for its R&D teams.
Why BI Bid Farewell To Biosimilars
The German group pharma's chief told Scrip "innovation drives the business" and confirmed that biosimilars have been abandoned apart from its Humira version Cyltezo in the US.
More from Business
More from Scrip
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.